This Phase II trial explores CBD for anxiety in breast cancer patients, indicating safety and potential anxiolytic effects despite no primary outcome success.
Ron Renaud’s new obesity biotech, Kailera, has $400M to go straight to Phase 3
There’s major money behind efforts to speed the next significant obesity company to the market. First, it was Metsera, which launched in April with …